ArticleBMC ophthalmology2025
Paracentral acute middle maculopathy as a major clinical manifestation of adenosine deaminase-2 deficiency.
Article in BMC ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAdenosine deaminase-2 (ADA2) deficiency is a rare autosomal recessive autoinflammatory syndrome, typically presenting in young patients with a broad spectrum of phenotypes. These phenotypes usually include primary immune deficiencies, livedo reticularis, and hematological abnormalities. Visual loss associated with ADA2 deficiency is uncommon and, when it does occur, is often linked to major vascular involvement, such as occlusion of the ophthalmic arteries. Paracentral acute middle maculopathy (PAMM) is an optical coherence tomography (OCT) finding characterized by ischemia at the inner retinal capillary complex rather than the major retinal vessels. It has been previous associated with a variety of systemic diseases, retinal vascular diseases, and drugs side-effects, but never with ADA2 deficiency until this moment. CASE PRESENTATION: A 31-year-old woman with a presumptive diagnosis of common variable immunodeficiency and livedo reticularis presented with sudden onset severe visual loss in the left eye due to PAMM followed a few weeks later by a lacunar stroke. An extensive laboratory investigation including genetic testing led to the diagnosis of ADA2 deficiency, a rare recessively inherited autoinflammatory syndrome. Treatment regimen was switched to anti-TNF-α inhibitors, leading to disease remission with no further vascular events over a two-year follow-up period.
conclusionThis case serves to emphasize the importance of considering ADA2 deficiency in patients with PAMM, particularly when it occurs in young patients with a history of strokes and/or immunological abnormalities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.